The Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination. A Randomized, Double-Blind, Fixed Dose, Phase 3 Compaison between ACAM2000 and Dryvax Smallpox Vaccines.

Grants and Contracts Details

StatusFinished
Effective start/end date2/5/042/28/08

Funding

  • PPD Development: $173,011.00